Patent Examiner Sun Jae Yoo
Art Unit 1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions · Tech Center 1600 · 413 applications filed 2021–2026
Sun Jae Yoo is a USPTO patent examiner in Art Unit 1621 (Heterocyclic Drug Compounds & Pharmaceutical Compositions) with 413 applications from filing years 2021–2026. Examiner Yoo's allowance rate is 66.9%, below the 82.2% USPTO average for applications filed in the same years. The examiner ranks harder than 76% of examiners. In 2021, decided applications with an examiner interview were allowed 37.2 percentage points more often than those without.
Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology
Overview
FreeExaminer details
- Art unit1621 · Heterocyclic Drug Compounds & Pharmaceutical Compositions
- Title / gradePrimary Patent Examiner · GS-14
- Service20 years
- PhoneOn each office action
- In USPTO recordsYOO, SUN JAE
Examiner Yoo can allow an application without a supervisory sign-off.
How to improve your odds with Examiner Yoo
- The data favors an interview. Interviewed cases were allowed more often in all 4 measured years, by 5.0 to 40.0 points.
- Plan for the timeline. First office action averages 818 days vs the 615-day USPTO norm.
- Expect a §112. Definiteness & disclosure is the most-issued rejection (77), and applicants overcame it 80.0% of the time.
- The data favors an RCE here. Cases with an RCE were allowed more often in both measured years, by 28.3 to 42.6 points.
Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.
Rejection patterns & how they get overcome
FreeOf the 21 winning responses to Examiner Yoo's §112 rejections that Boundly has classified, 13 (62%) amended without arguing, and 8 amended the claims and argued. Each winning response, with its arguments and claim amendments, is in the file wrapper.
Just got an office action from Examiner Yoo?
Draft your response with Examiner Yoo's record and Art Unit 1621's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See office action responses in AI Studio.
Trends
| Year | Interview rate | Allowance w/ interview | Allowance w/o | Delta |
|---|---|---|---|---|
| 2024 | 16.0% | 100.0% | 60.0% | +40.0pp |
| 2023 | 16.0% | 100.0% | 63.2% | +36.8pp |
| 2022 | 13.4% | 66.7% | 61.7% | +5.0pp |
| 2021 | 33.6% | 93.5% | 56.3% | +37.2pp |
RCE behavior
Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Yoo.
| Year | RCE rate | Allowance w/ RCE | Allowance w/o | Delta |
|---|---|---|---|---|
| 2022 | 15.9% | 100.0% | 57.4% | +42.6pp |
| 2021 | 15.5% | 92.3% | 64.0% | +28.3pp |
Recent outcomes
Free🔒 Case detail for members| App # | Title | Outcome | OAs | Arguments & redline |
|---|---|---|---|---|
| 18/024010 | Use of PCSK9 Inhibitor in Preparation of Product for Treating Multiple Diseases | Patented | 1 | 🔒 View |
| 18/343326 | KRAS G12C Inhibitors | Patented | 0 | 🔒 View |
| 17/909589 | 2,5- or 2,6-Disubstituted Hydroquinone Derivatives with at Least One Carboxy, Sulfo or Amido Group Useful as Medicaments | Patented | 2 | 🔒 View |
| 18/794040 | Acrylate Derivative, Use and Production Intermediate Compound of the Same | Patented | 0 | 🔒 View |
Art Unit 1621 technology
Frequently asked questions
What is Examiner Sun Jae Yoo's allowance rate?
Is Examiner Yoo a hard examiner?
Do examiner interviews help with Examiner Yoo?
What is Examiner Yoo's most common rejection?
Is an RCE worth filing with Examiner Yoo?
How long until the first office action from Examiner Yoo?
Put Examiner Yoo's data to work on your next response.
Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.